Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | PDE2A | O00408 | 7/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5906300 | 0.82 | ATM (0.59) | ATMKMT2ASYKHIF1ALMNA | |
| SCHEMBL23565228 | 0.81 | ABHD16A (0.44) | ATMKMT2ALMNASMN1; SMN2 | |
| SCHEMBL8721162 | 0.80 | L3MBTL1 (0.56) | ATMPDE2AKMT2AKDM4ENPBWR1 | |
| SCHEMBL7067294 | 0.78 | GAA (0.47) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL13114729 | 0.78 | NPC1 (0.47) | ATMKMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL3170478 | 0.78 | MAPK1 (0.47) | ATMKMT2AHIF1ALMNASMN1; SMN2 | |
| SCHEMBL9226052 | 0.77 | L3MBTL1 (0.43) | ATMPDE2AKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7838265 | 0.74 | CDK4 (0.54) | — | |
| SCHEMBL8386511 | 0.72 | HCAR1 (0.47) | KMT2ALMNAKDM4E | |
| SCHEMBL18656523 | 0.71 | ALDH1A1 (0.34) | ATMKMT2ALMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099725-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099725-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | PPARA, PPARG, PPARD | ATM 2924/4885PDE2A 1312/4885KMT2A 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.